By promoting tumor progression and contributing to an immunosuppressive microenvironment, IFI16 presents a potential therapeutic target to restore immune surveillance and improve treatment outcomes in HPV-positive cervical cancer (Figure 4) (53). This evidence concerns the gene IFI16 and neoplasm.